Sana Biotechnology to Build Production in Seattle Area from California – GeekWire

Sana CEO Steve Har. (Photo by Sana)

After announcing plans last summer to build its production facility in California, Sana Biotechnology changed course. The cell and gene therapy company will now develop an 80,000-square-foot facility in Botel, Washington, near its headquarters in Seattle.

The new site is expected to save more than $ 100 million previous site in the San Francisco Bay Area. The move also allows the company to engage the Seattle workforce to produce cell therapies set up by institutions such as Fred Hutchinson’s Cancer Centers and a number of cell therapy companies.

Sana will lease the existing building and build it for production.

“This new facility allows us to continue to develop our domestic production without the expected impact on the timing of our programs and in a more cost-effective way,” said Sana’s CEO. Steve Har y statement On Wednesday we announce a new site. “The important thing is that we continue to attract the strong talent needed to realize this vision and our pipeline on a larger scale,” he added.

Sana also announced that it has hired a former head of cell therapy production at Bristol Myers Squibb, Snow Patel, who will now be Sana’s production manager. Patel was also previously the head of the cellular therapy plant Bothell BMS, which produces a product for cellular therapy “CAR T” Breyanzi.

Last February, Sana raised $ 587 million became public y the largest ever IPO for the preclinical stage of the biotechnology company. The company expects to submit its first two applications for new research this year to the U.S. Food and Drug Administration, which is a key step toward clinical trials, Sana’s vice president of finance said. Nicole Keith said GeekWire.

These applications will be for two CAR T-cell therapy products for B-cell malignancies. One is a product derived from donor cells, and the other is a product designed to deliver therapeutic cargo inside the body by fusing with T cells.

Ultimately, the company seeks to produce its products in a new building when they enter the later stages of clinical development and early commercialization.

The company no longer plans to build the previously announced facility, which was to be about twice the size of the Botel plant. “We have not announced specific lease plans in California at this time, but we are confident that we will be able to find a solution quickly,” Keith said.

The new facility will complement a growing list of biopharmaceutical manufacturing operations in the Seattle area. Lyell Immunopharma has completed cell production at Botel last yearand Sigen recently announced he will build a new 270,000-square-foot facility in Everett. Bill Gates recently cut the ribbon at the regional vaccine plant built by Inventprise, and Just-Evotec Biologics also has new regional plant.

In addition to hiring Patel, Sana brought on Julie Lepin as head of the rationing, safety and quality department. Lepin previously served as vice president of oncology regulation at Amgen.

Source link